These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 14577649)

  • 1. Transcription factors as molecular targets: molecular mechanisms of decoy ODN and their design.
    Tomita N; Ogihara T; Morishita R
    Curr Drug Targets; 2003 Nov; 4(8):603-8. PubMed ID: 14577649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of decoy oligodeoxynucleotides-based approach to renal diseases.
    Tomita N; Azuma H; Kaneda Y; Ogihara T; Morishita R
    Curr Drug Targets; 2004 Nov; 5(8):717-33. PubMed ID: 15578952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic potential of decoy oligonucleotides strategy in cardiovascular diseases.
    Tomita N; Ogihara T; Morishita R
    Expert Rev Cardiovasc Ther; 2003 Sep; 1(3):463-70. PubMed ID: 15030273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene therapy with transcription factor decoy oligonucleotides as a potential treatment for cardiovascular diseases.
    Tomita N; Azuma H; Kaneda Y; Ogihara T; Morishita R
    Curr Drug Targets; 2003 May; 4(4):339-46. PubMed ID: 12699354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of transcription factor "decoy" strategy as means of gene therapy and study of gene expression in cardiovascular disease.
    Morishita R; Higaki J; Tomita N; Ogihara T
    Circ Res; 1998 Jun; 82(10):1023-8. PubMed ID: 9622154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential therapeutic applications of decoy oligonucleotides.
    Tomita N; Morishita R; Tomita T; Ogihara T
    Curr Opin Mol Ther; 2002 Apr; 4(2):166-70. PubMed ID: 12044038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Oligonucleotide-based therapy as a potential new pharmacotherapy].
    Morishita R
    Nihon Yakurigaku Zasshi; 2000 Mar; 115(3):123-30. PubMed ID: 10876797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oligonucleotide-based gene therapy for cardiovascular disease: are oligonucleotide therapeutics novel cardiovascular drugs?
    Morishita R; Aoki M; Kaneda Y
    Curr Drug Targets; 2000 Jul; 1(1):15-23. PubMed ID: 11475534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic potential of oligonucleotide-based therapy in cardiovascular disease.
    Morishita R; Kaneda Y; Ogihara T
    BioDrugs; 2003; 17(6):383-9. PubMed ID: 14614761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An oligonucleotide decoy for transcription factor E2F inhibits mesangial cell proliferation in vitro.
    Tomita N; Horiuchi M; Tomita S; Gibbons GH; Kim JY; Baran D; Dzau VJ
    Am J Physiol; 1998 Aug; 275(2):F278-84. PubMed ID: 9691019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Application of decoy strategy].
    Morishita R; Ogihara T
    Nihon Rinsho; 1996 Sep; 54(9):2583-90. PubMed ID: 8890596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular strategy using cis-element 'decoy' of E2F binding site inhibits neointimal formation in porcine balloon-injured coronary artery model.
    Nakamura T; Morishita R; Asai T; Tsuboniwa N; Aoki M; Sakonjo H; Yamasaki K; Hashiya N; Kaneda Y; Ogihara T
    Gene Ther; 2002 Apr; 9(8):488-94. PubMed ID: 11948373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcription factor decoy oligonucleotide-based therapeutic strategy for renal disease.
    Tomita N; Kashihara N; Morishita R
    Clin Exp Nephrol; 2007 Mar; 11(1):7-17. PubMed ID: 17384993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of transcriptional cis-elements, angiotensinogen gene-activating elements, of angiotensinogen gene in blood pressure regulation.
    Morishita R; Higaki J; Tomita N; Aoki M; Moriguchi A; Tamura K; Murakami K; Kaneda Y; Ogihara T
    Hypertension; 1996 Mar; 27(3 Pt 2):502-7. PubMed ID: 8613193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumoral injection of oligonucleotides to the NF kappa B binding site inhibits cachexia in a mouse tumor model.
    Kawamura I; Morishita R; Tomita N; Lacey E; Aketa M; Tsujimoto S; Manda T; Tomoi M; Kida I; Higaki J; Kaneda Y; Shimomura K; Ogihara T
    Gene Ther; 1999 Jan; 6(1):91-7. PubMed ID: 10341880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene therapy for attenuating cardiac allograft arteriopathy using ex vivo E2F decoy transfection by HVJ-AVE-liposome method in mice and nonhuman primates.
    Kawauchi M; Suzuki J; Morishita R; Wada Y; Izawa A; Tomita N; Amano J; Kaneda Y; Ogihara T; Takamoto S; Isobe M
    Circ Res; 2000 Nov; 87(11):1063-8. PubMed ID: 11090553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of novel decoy oligonucleotides: advantages of circular dumb-bell decoy.
    Tomita N; Tomita T; Yuyama K; Tougan T; Tajima T; Ogihara T; Morishita R
    Curr Opin Mol Ther; 2003 Apr; 5(2):107-12. PubMed ID: 12772498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel E2F decoy oligodeoxynucleotides inhibit in vitro vascular smooth muscle cell proliferation and in vivo neointimal hyperplasia.
    Ahn JD; Morishita R; Kaneda Y; Kim HS; Chang YC; Lee KU; Park JY; Lee HW; Kim YH; Lee IK
    Gene Ther; 2002 Dec; 9(24):1682-92. PubMed ID: 12457282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular therapy to inhibit NFkappaB activation by transcription factor decoy oligonucleotides.
    Morishita R; Tomita N; Kaneda Y; Ogihara T
    Curr Opin Pharmacol; 2004 Apr; 4(2):139-46. PubMed ID: 15063357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of NFkappaB activation using cis-element 'decoy' of NFkappaB binding site reduces neointimal formation in porcine balloon-injured coronary artery model.
    Yamasaki K; Asai T; Shimizu M; Aoki M; Hashiya N; Sakonjo H; Makino H; Kaneda Y; Ogihara T; Morishita R
    Gene Ther; 2003 Feb; 10(4):356-64. PubMed ID: 12595894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.